文献速递肥胖与代谢综合征

Petrelintide(一种人胰淀素类似物)治疗肥胖的2期随机双盲安慰剂对照试验(ZUPREME 1)

Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-09-29

BACKGROUND: Petrelintide is a novel, long-acting amylin analogue being developed for long-term treatment of obesity, leveraging a mechanism of action distinct from incretin-based treatments.…

要点

  • 最常见不良事件为恶心(20% vs 6%),呕吐少见(3% vs 6%)。

核心结论

  • Petrelintide实现了具有临床意义的体重下降,除剂量递增期间以轻度恶心为主的胃肠道耐受性与安慰剂相似,支持其作为长期肥胖疗法的进一步评估。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2期试验,在波兰、罗马尼亚和美国的32个中心(公立医院和私人诊所)开展。
  • 纳入年龄≥18岁、无2型糖尿病、BMI≥30 kg/m²或BMI≥27 kg/m²合并高血压和/或血脂异常的患者。
  • 随机化通过中央交互响应技术系统进行,按是否参与MRI分层;受试者、试验人员和资助方对治疗分配设盲,但对不同维持剂量不设盲。
  • 主要终点为第28周体重较基线百分比变化;分析纳入所有随机分配且至少接受一剂治疗的受试者。

临床怎么用

  • Petrelintide每周一次皮下注射在无2型糖尿病的肥胖成人中可显著降低体重,且除剂量递增期轻度恶心外胃肠道耐受性与安慰剂相似。
  • 该结果为2期试验,支持进一步开展长期肥胖治疗的评估,尚不能直接用于临床处方决策。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Petrelintide is a novel, long-acting amylin analogue being developed for long-term treatment of obesity, leveraging a mechanism of action distinct from incretin-based treatments. This phase 2 trial aimed to evaluate the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity. METHODS: This multicentre, randomised, double-blind, placebo-controlled trial involved 32 sites (public hospitals and private clinics) in Poland, Romania, and the USA. Adults aged at least 18 years without type 2 diabetes, with a BMI of at least 30 kg/m2 or with a BMI of at least 27 kg/m2 with hypertension or dyslipidaemia, or both, were randomly assigned (5:1) to self-administered subcutaneous injections of once-weekly maintenance doses of petrelintide (1·0-9·0 mg) or placebo for 42 weeks including dose escalation. Randomisation was done via a central interactive response technology system and was stratified by MRI participation. Participants, trial staff, and the study funder were masked to treatment assignment but not to different maintenance doses; masking was maintained by use of identical vials for petrelintide and placebo. The primary endpoint was percentage change in bodyweight from baseline after 28 weeks. Analyses included all randomly assigned participants who received at least one dose. Missing data were assumed to be missing at random. The trial is registered with ClinicalTrials.gov (NCT06662539) and the Clinical Trials Information System (2024-512549-18) and was completed on Mar 7, 2026. FINDINGS: From Dec 9, 2024, to Feb 25, 2025, we screened 714 participants, of whom 493 were randomly assigned and 485 received at least one dose of petrelintide or placebo. 79 participants received at least one dose of treatment with petrelintide 1·0 mg, 81 with petrelintide 2·5 mg, 83 with petrelintide 5·0 mg, 79 with petrelintide 7·0 mg, 82 with petrelintide 9·0 mg, and 81 with placebo. 255 (53%) participants were female, 230 (47%) were male, mean age was 47 (SD 12) years, mean bodyweight 107·1 kg (20·3), mean BMI 36·7 kg/m2 (5·5), and 419 (86%) were White. Mean percentage change in bodyweight from baseline after 28 weeks (efficacy estimand) was -7·9% (95% CI -9·0 to -6·7) with petrelintide 1·0 mg, -7·9% (-9·0 to -6·7) with petrelintide 2·5 mg, -9·8% (-10·9 to -8·6) with petrelintide 5·0 mg, -9·3% (-10·5 to -8·2) with petrelintide 7·0 mg, and -9·4% (-10·5 to -8·3) with petrelintide 9·0 mg versus -1·7% (-2·8 to -0·5) with placebo. Estimated treatment differences versus placebo were -6·2% (-7·9 to -4·5) with petrelintide 1·0 mg, -6·2% (-7·8 to -4·5) with petrelintide 2·5 mg, -8·1% (-9·7 to -6·5) with petrelintide 5·0 mg, -7·7% (-9·3 to -6·0) with petrelintide 7·0 mg, and -7·7% (-9·4 to -6·1) with petrelintide 9·0 mg. Bodyweight continued to decline to week 42, with reductions of up to -10·7% with petrelintide. The most common adverse event with petrelintide was nausea (79 [20%] of 404 participants vs five [6%] participants with placebo). Vomiting was infrequent with petrelintide (12 [3%] participants vs five [6%] with placebo); active treatment and placebo had similarly low rates for diarrhoea (30 [7%] participants vs six [7%] with placebo) and constipation (28 [7%] vs three [4%] with placebo). No deaths were reported. INTERPRETATION: Petrelintide achieved clinically meaningful weight reduction and had similar gastrointestinal tolerability to that of placebo apart from predominantly mild nausea during dose escalation, supporting further evaluation as a long-term obesity therapy. FUNDING: Zealand Pharma.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Garvey WT, Ard J, Connery L, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42810355. doi:10.1016/S2213-8587(26)00213-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。